GLP-1 Website
Claim Screener
Scan your public website for text and image patterns commonly flagged in FDA warning letters involving compounded GLP-1 marketing, telehealth advertising, and product-source confusion.
The review covers one selected public page. Your report includes supporting evidence, FDA warning-letter references and a priority checklist.
What the Screener Checks
Company branding on medication containers or labels
FDA-approved or FDA-licensed pharmacy and facility claims
Active-ingredient comparisons tied to compounded products
Generic, equivalent, same-results or alternative claims
Clinical-proof and safety-and-effectiveness claims about compounded formulations
FDA-approved active-ingredient wording
Brand-drug names tied to a compounded-product sales presentation
Related disclaimers as context for an identified FDA-pattern match
Grounded in FDA warning-letter patterns
Each reported finding is tied to a documented claim pattern. Historical letters are used as examples; they do not determine the status of the website being reviewed. Pricing, testimonials, plain vials and ordinary company logos are not standalone findings.
What You Receive
A focused review of one selected public page
Exact supporting text excerpts and available image evidence
Verified FDA warning-letter references for each finding
A cautious explanation of the identified pattern
A Telehealth.law PDF report
A priority checklist limited to findings actually identified
What This Tool Does Not Do
This is a general educational and issue-spotting tool. It is not legal advice. Please review the following limitations carefully.
Does not provide legal advice
Does not determine whether any website is legal, illegal, compliant, or noncompliant
Does not replace attorney review
Does not evaluate non-public workflows, contracts, pharmacy agreements, or paid advertising
Does not create an attorney-client relationship